CClinicalTrials.gg
Status unknownNCT05098951Updated Nov 10, 2021

Acupuncture for Stiffness of Joint Related to Aromatase Inhibitors in Patients With Early-Stage Breast Cancer

An interventional study of Acupuncture in Breast Cancer and Stiffness of Hand, Not Elsewhere Classified, sponsored by Affiliated Hospital of Qinghai University. Status unknown at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-11-10.

Sponsored by Affiliated Hospital of Qinghai University · Not applicable, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Nov 2021), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Study summary

RATIONALE: Acupuncture may help relieve joint stiffness related to aromatase inhibitors in patients with early-stage breast cancer.

PURPOSE: This single arm clinical study aims to evaluate how well acupuncture as a non-pharmacological treatment, works in treating patients with joint stiffness related to aromatase inhibitors (AIs) in patients with early-stage breast cancer.

Read the detailed description

Objectives of this study:

Primary objective:

To evaluate whether acupuncture as a non-pharmacological treatment, administered twice weekly for 6 weeks can significantly reduce joint stiffness related to AIs in women with early-stage breast cancer as measured by the Western Ontario and McMasters Universities Osteoarthritis (WOMAC) stiffness score at weeks 6.

Secondary objectives:

To evaluate the effect of acupuncture on joint stiffness measured by the WOMAC stiffness score at weeks 12.

To evaluate the effect of acupuncture on joint stiffness measured by the Modified Score for the Assessment of Chronic Rheumatoid Affections of the Hands (M-SACRAH) stiffness score at weeks 6 and weeks 12.

To evaluate the effects of acupuncture on quality of life (QOL) assessed by the Functional Assessment of Cancer Therapy-Endocrine Subscales (FACT-ES) at weeks 6 and weeks 12.

To evaluate the safety and tolerability of acupuncture in the enrolled patients.

To identify potential genetic determinants to response to acupuncture.

02

Conditions studied

  • Breast Cancer
  • Stiffness of Hand, Not Elsewhere Classified

Browse trials for

Keywords

  • Breast cancer
  • Stiffness
  • Aromatase inhibitor
  • Acupuncture
  • High altitude
03

In context

Breast Neoplasms

12,543 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's planned enrollment of 52 is below the median of 72 across 9,302 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Affiliated Hospital of Qinghai University is the lead sponsor of 17 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. History of stage I-III breast cancer and free of disease by clinical examination
  2. Postmenopausal or premenopausal with ovarian suppression
  3. Currently receiving aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) treatment
  4. With joint stiffness attributed to the use of aromatase inhibitors
  5. Having had joint stiffness for at least 1 months
  6. Having had at least 15 days with stiffness in the preceding 30 days

Exclusion criteria

Exclusion Criteria:

  1. Women with recurrent or metastatic breast cancer
  2. Women having finished chemotherapy or radiation therapy less than 1 months prior to enrollment
  3. Women with history of bleeding disorder
  4. Women with joint stiffness attributed to inflammatory arthritis, such as rheumatoid arthritis, spondy loarthritis and osteoarthritis
  5. Women having joint stiffness prior to AI treatment
  6. Women that have received treatment of any kind for joint stiffness within the last 3 months
  7. Women that have previously received the acupuncture treatment before for any reason
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Patients with stiffness of joint receive acupuncture therapy

    This is a single arm study. All the enrolled patients will receive acupuncture twice weekly for 6 weeks then once weekly for another 6 weeks.

    Device: Acupuncture

Interventions

  • DeviceAcupuncture

    Patients with stiffness of joint receive acupuncture therapy twice weekly for 6 weeks and then once weekly for 6 weeks.

06

What researchers measure

Primary outcomes

  1. The change in stiffness score as measured by the Western Ontario and McMasters Universities Osteoarthritis (WOMAC)

    The change in stiffness score as measured by the Western Ontario and McMasters Universities Osteoarthritis (WOMAC) at the end of week 6 of intervention compared to that at baseline.

    Time frame: 6 weeks

Secondary outcomes

  1. The change in stiffness score as measured by the Modified Score for the Assessment of Chronic Rheumatoid Affections of the Hands (M-SACRAH)

    The change in stiffness score as measured by the Modified Score for the Assessment of Chronic Rheumatoid Affections of the Hands (M-SACRAH) at the end of week 6 of intervention compared to that at baseline.

    Time frame: 6 weeks

07

Study locations

1 of 1 sites recruiting
  • Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University
    Xining, Qinghai 810000, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05098951
Lead sponsor
Affiliated Hospital of Qinghai University
Responsible party
Jiuda Zhao (Professor, Affiliated Hospital of Qinghai University) — Principal investigator
First posted
Oct 29, 2021
Start date
Oct 20, 2021
Primary completion
Sep 1, 2022 (estimated)
Completion
Jun 1, 2023 (estimated)
Last update
Nov 10, 2021

Study contacts

Dengfeng Ren
Contact
dengfeng1104@126.com
+8613086297659
Jiuda Zhao
principal investigator · the Affiliated Hospital of Qinghai University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion